Clinical trials generate more data than ever before.
From EDC systems, laboratory data, clinical trial management systems (CTMS), and safety data to operational and real-world sources, the volume of information flowing through clinical programs continues to grow.
At the same time, AI is creating new opportunities to analyze that information at a scale that wasn’t previously possible. Organizations can no longer afford to treat quality as something that gets evaluated at the end of a study. Increasingly, they need to identify risks, signals, and data issues while there is still time to act.
That’s creating a new challenge for clinical teams. The industry’s problem is no longer access to data. It’s deciding where experts should focus their attention.
More Data Hasn’t Made Review Easier
For years, life sciences organizations have invested heavily in data platforms, automation, and analytics. Yet clinical trial delays remain stubbornly persistent.
According to the Tufts Center for the Study of Drug Development, approximately 80% of clinical trials still miss their planned enrollment timelines. If the industry has more data, more technology, and more AI than ever before, why do delays remain so persistent?
A core reason is that visibility alone doesn’t create action. Data may be available, but it’s not always organized, prioritized, or presented in a way that helps teams determine what requires attention first. Clinical data managers, medical reviewers, and biostatisticians still spend significant time reconciling information across multiple systems, reviewing discrepancies, and tracking down answers before meaningful analysis can even begin.
Clinical teams are being asked to do all of this at once:
- Review growing volumes of study data
- Identify potential data issues and safety or efficacy signals earlier
- Resolve discrepancies faster
- Support increasingly complex protocols
- Deliver cleaner, submission-ready datasets
The result is a familiar pattern. Teams accumulate more information than ever before, while the people responsible for reviewing it face increasing pressure to move faster without sacrificing quality, safety, or compliance.
The Shift Toward Risk-Based Clinical Data Review
One of the most important changes happening in clinical development today is the move toward more proactive and risk-based approaches.
The goal isn’t simply reviewing data faster. It’s bringing quality, oversight, and risk identification earlier into the trial lifecycle. Instead of treating every data point equally, organizations are asking a different question: Where should we focus first?
As data volumes continue to grow, that question becomes increasingly difficult to answer. Clinical teams can’t scale review activities in direct proportion to the amount of information flowing through a study. They need better ways to prioritize attention, identify meaningful risk, collaborate, and focus effort where it can have the greatest impact.
The shift requires a more deliberate approach to review—one that combines human expertise with AI-driven prioritization to identify meaningful signals sooner, rather than treating every data point with the same level of urgency.
Why AI-Driven Clinical Review Is Becoming a Competitive Advantage
When people think about clinical trial performance, they often focus on enrollment, protocol design, or study execution. But clinical data review plays an equally important role.
The faster teams can identify anomalies, review discrepancies, detect potential safety or efficacy signals, and align around a common view of study performance, the faster they can make informed decisions. Instead of spending time searching for information, teams need critical signals surfaced in the moments they matter most. That shift is already underway across the industry.
Quality is becoming part of the process from the beginning rather than something that gets evaluated after the fact.”
— Prabha Ranganathan, Associate Vice President, Life Sciences
Organizations are increasingly moving quality and oversight earlier in the trial lifecycle rather than relying on downstream review and remediation. As a result, clinical data review is becoming less about finding issues after they occur and more about identifying risks while there is still time to act.
Better Decisions Require More Than Visibility
Which discrepancies represent meaningful risk? What signals may indicate a developing safety concern? Which issues can wait, and which require action right now?
These are the questions that can’t be answered by another dashboard alone. They require a trusted view of data, clear prioritization, and the ability to connect signals to action while there is still time to influence the outcome.
That’s why clinical data review is evolving from a process focused on finding issues to one focused on identifying risk sooner.
Perficient’s Clinical Data Repository and Review solution was designed to support that shift. By combining a unified clinical data foundation with agentic AI capabilities, it helps organizations move beyond data aggregation and turn growing volumes of clinical information into faster, more informed decisions.
As data volumes continue to grow, competitive advantage increasingly comes from finding critical signals sooner—not reviewing more data.
The Next Challenge Isn’t More Data
The life sciences industry has spent years solving the problem of data collection. The next challenge is helping clinical teams keep up with what that data is trying to tell them.
Organizations that gain an advantage won’t necessarily be the ones generating more information. They’ll be the ones that help their experts find the right signals faster, make better decisions sooner, and act before risks impact study outcomes.
Interested in seeing what that could look like in practice? Reach out to schedule a demo with Perficient’s Healthcare & Life Sciences team to explore how AI-driven clinical review can help your teams focus less on administrative work and more on the decisions that move studies forward.
